Genetic information has helped researchers and physicians to identify major risk factors for disease and to manage health risks more effectively through improved prevention, screening and family history. The Human Pedigree Analysis Resource (HPAR) designs database tools and methods for the collection and analysis of pedigree data. The HPAR staff consists of the facility director, two Co-Directors, an Informatics Manager, four programmer analysts, a system analyst II and a graduate research assistant. The HPAR database currently supports the Human Clinical Cancer Genetics clinics for breast, ovarian, and colorectal cancers, and provides support to researchers investigating the genetic basis of several other cancer sites. The HPAR has been successful in providing data management support for the collection and analysis of family history information for pedigree data collection, clinical and laboratory tracking information, and laboratory results. During the past 5 years, the HPAR has had 15 users representing 13 CCSG programs, of which 88% are peer-review funded. Long-term objectives are 1) to develop a more advanced genetics database system to extend the HPAR's comprehensive electronic family history information system. This advanced system will include a Web application that allows patients to complete an extended family-history questionnaire prior to their appointment with a genetic counselor. Capturing data before a patient contact will allow genetic counselors to perform automated genetic counseling assessments of the patient's risk for cancer development and the probability of carrying a cancer-susceptibility mutation. 2) To convert the existing SQL server from a two-tier SQL server-based client-server structure to a three-tier structure to make services easily available to other clinicians who need pedigrees drawn from family history information. 3) To develop an in-house interactive computer program for drawing family pedigrees and linking family data gathered for genetics research. This program will be a valuable visual tool for geneticists in identifying clusters of inherited traits and genotypes. Short-term objectives are 1) to avoid duplication of patient data by making informatics tools easily-accessible and to use them to integrate information from different resources (CRIS, CARE, and Clinic Station);2) to provide analytical support for the application of complex genetic software to identify inherited susceptibility to cancers including application of risk assessment software, linkage analysis and genome-wide association analysis studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-35
Application #
8144410
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
35
Fiscal Year
2010
Total Cost
$160,071
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications